Dexmedetomidine Nasal Spray versus Intravenous Infusion on Quality of Recovery after Laparoscopic Cholecystectomy: A Randomized, Double-blind, Three-arm Controlled Trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2600119543

Enrollment

Unknown

Registered

2026-02-28

Start date

2026-03-02

Completion date

Unknown

Last updated

2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gallstones, cholecystitis

Interventions

0.9% saline group:0.9% saline

Dexmedetomidine nasal spray group:Dexmedetomidine nasal spray

Intravenous Dexmedetomidine Infusion group:Intravenous Dexmedetomidine Infusion

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. 18–80 years old; 2. BMI 18–35 kg/m^2; 3. ASA classification I-III; 4. Elective general anesthesia LC surgery and signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Severe sinus bradycardia (HR <50 bpm); 2. Second-degree or higher AVB, EF <40%; 3. Obstructive sleep apnea; 4. Chronic pain / opioid dependence; 5. Use of a2-agonists/antagonists within 1 week before surgery; 6. Unable to cooperate with nasal spray administration and complete questionnaires

Design outcomes

Primary

Measure	Time frame
24-h quality of recovery;	—

Secondary

Measure	Time frame
Bradycardia;Hypotension;Length of PACU stay;QoR-15 scores in each dimension;24-h analgesic consumption;Time to first flatus;Days of postoperative hospital stay;	—

Countries

China

Contacts

Public ContactKe Peng

The First Affiliated Hospital of Soochow University

pengke0422@163.com+86 512 67780156

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 14, 2026